NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.54) per share which met the analyst consensus estimate.
Piper Sandler Maintains Overweight on Olo, Raises Price Target to $39
Piper Sandler analyst Brent Bracelin maintains Olo (NYSE:OLO) with a Overweight and raises the price target from $35 to $39.